Yüksel Ürün shared on X:
“Omitting the 5-FU bolus from regimens like FOLFOX, FOLFIRI, and FOLFIRINOX in metastatic GI cancers may reduce toxicity without impacting overall survival.”
Authors: Chengwei Peng, Saad Saffo, Paul E. Oberstein, Michael Shusterman, Charlene Thomas, Daniel J. Becker, Jordan D. Berlin, Lawrence P. Leichman, Ben Boursi, Anil B. Nagar, Shun Yu
Source: Yüksel Ürün/X
More posts featuring Yüksel Ürün on oncodaily.com
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.